An open-label, multicenter phase Ib/II clinical study to evaluate the safety and efficacy of LBL-024 combined with etoposide and platinum in the first-line treatment of patients with advanced neuroendocrine carcinoma (NEC)
Agree to follow the trial treatment regimen and visit schedule, voluntarily enroll, and sign the written informed consent.
aged 18-75 years (including borderline values) at the time of signing the informed consent form
The Eastern Cooperative Oncology Group's physical status scoring standard (ECOG) is 0~1.
The expected survival time is at least 12 weeks.
Subjects who underwent major organ surgery (excluding needle biopsy) or significant trauma within 4 weeks prior to the initial use of the investigational drug, or require elective surgery during the trial period
Use of immunomodulatory drugs within 14 days prior to the initial use of the investigational drug, including but not limited to thymosin, interleukin, and interferon
Subjects with an active infection that currently requires intravenous anti-infective therapy.
Clinically uncontrollable pleural effusion, pericardial effusion, and requiring repeated drainage or medical intervention.